Suppr超能文献

迈向结核病消除的进展和结核病规划绩效 - 国家结核病指标项目,2016-2022 年。

Progress Toward Tuberculosis Elimination and Tuberculosis Program Performance - National Tuberculosis Indicators Project, 2016-2022.

机构信息

Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC.

出版信息

MMWR Surveill Summ. 2024 Jun 6;73(4):1-18. doi: 10.15585/mmwr.ss7304a1.

Abstract

PROBLEM/CONDITION: Elimination of tuberculosis (TB) is defined as reducing TB disease incidence in the United States to less than 1 case per million persons per year. In 2022, TB incidence in the United States was 2.5 TB cases per 100,000 persons. CDC's TB program developed a set of national TB indicators to evaluate progress toward TB elimination through monitoring performance of state and city TB program activities. Examining TB indicator data enables state- and city-level TB programs to identify areas for program evaluation and improvement activities. These data also help CDC identify states and cities that might benefit from technical assistance.

PERIOD COVERED

The 5-year period for which the most recent data were available for each of five indicators: 1) overall TB incidence (2018-2022), 2) TB incidence among non-U.S.-born persons (2018-2022), 3) percentage of persons with drug susceptibility results reported (2018-2022), 4) percentage of contacts to sputum acid-fast bacillus (AFB) smear-positive TB patients with newly diagnosed latent TB infection (LTBI) who completed treatment (2017-2021), and 5) percentage of patients with completion of TB therapy within 12 months (2016-2020).

DESCRIPTION OF SYSTEM

The National TB Indicators Project (NTIP) is a web-based performance monitoring tool that uses national TB surveillance data reported through the National TB Surveillance System and the Aggregate Reports for TB Program Evaluation. NTIP was developed to facilitate the use of existing data to help TB program staff members prioritize activities, monitor progress, and focus program improvement efforts. The following five indicators were selected for this report because of their importance in Federal TB funding allocation and in accelerating the decline in TB cases: 1) overall TB incidence in the United States, 2) TB incidence among non-U.S.-born persons, 3) percentage of persons with drug susceptibility results reported, 4) percentage of contacts to sputum AFB smear-positive TB cases who completed treatment for LTBI, and 5) percentage of patients with completion of TB therapy within 12 months. For this report, 52 TB programs (50 states, the District of Columbia, and New York City) were categorized into terciles based on the 5-year average number of TB cases reported to National TB Surveillance System. This grouping allows comparison of TB programs that have similar numbers of TB cases and allocates a similar number of TB programs to each category. The following formula was used to calculate the relative change by TB program for each indicator: [(% from year 5 - % from year 1 ÷ % from year 1) × 100].

RESULTS

During the 5-year period for which the most recent data were available, most TB programs had improvements in reducing overall TB incidence (71.2%) and increasing the percentage of contacts receiving a diagnosis of LTBI who completed LTBI treatment (55.8%); the majority of programs (51.0%) also had improvements in reducing incidence among non-U.S.-born persons. The average percentage of persons with drug susceptibility results reported in most jurisdictions (28 of 52, [53.9%]) met or exceeded the 5-year national average of 97% (2018-2022). The percentage of contacts to sputum acid-fast bacillus (AFB) smear-positive TB patients with newly diagnosed latent TB infection (LTBI) who completed treatment increased in 29 of 52 (55.8%) jurisdictions from 2017 to 2021, signifying that, for most jurisdictions, steps have been taken to enhance performance in this area. The average percentage of patients with completion of TB therapy within 12 months was at or above the national average of 89.7% in approximately two-thirds (32 of 52 [61.5%]) of jurisdictions.

INTERPRETATION

This report is the first to describe a 5-year relative change for TB program performance. These results suggest that TB programs are making improvements in activities that help identify persons with TB and LTBI and ensure patients complete treatment in a timely manner.

PUBLIC HEALTH ACTION

Use of NTIP data from individual TB programs enables a more detailed examination of trends in program performance and identification of areas for program improvement. Assessing indicator trends by TB program provides an opportunity to gain a better understanding of program performance in comparison to other programs. It can also facilitate communication between programs regarding successes and challenges in program improvement. This information is valuable for TB programs to allocate resources effectively and provide additional context on TB control for public health policymakers.

摘要

问题/状况:消除结核病(TB)的定义是将美国的结核病发病率降低到每年每百万人中少于 1 例。2022 年,美国的结核病发病率为每 10 万人中有 2.5 例结核病。疾病预防控制中心的结核病项目制定了一套国家结核病指标,通过监测州和城市结核病项目活动的绩效来评估向结核病消除的进展。检查结核病指标数据使州和城市一级的结核病项目能够确定项目评估和改进活动的领域。这些数据还帮助疾病预防控制中心确定可能受益于技术援助的州和城市。

涵盖期间

对于五个指标中的每一个,提供了最近可用的五年期间的数据:1)总体结核病发病率(2018-2022 年),2)非美国出生者的结核病发病率(2018-2022 年),3)报告的药敏结果百分比(2018-2022 年),4)新诊断潜伏性结核病感染(LTBI)的痰分枝杆菌(AFB)涂片阳性结核患者接触者中完成治疗的百分比(2017-2021 年),以及 5)在 12 个月内完成结核病治疗的患者百分比(2016-2020 年)。

系统描述

国家结核病指标项目(NTIP)是一个基于网络的绩效监测工具,使用通过国家结核病监测系统和综合报告进行的国家结核病监测数据。NTIP 的开发是为了方便利用现有数据,帮助结核病项目工作人员确定活动的优先顺序、监测进展情况,并将重点放在改进项目上。选择以下五个指标是因为它们在联邦结核病资金分配和加速结核病病例下降方面的重要性:1)美国总体结核病发病率,2)非美国出生者的结核病发病率,3)报告的药敏结果百分比,4)新诊断潜伏性结核病感染(LTBI)的痰分枝杆菌(AFB)涂片阳性结核患者接触者中完成治疗的百分比,以及 5)在 12 个月内完成结核病治疗的患者百分比。在本报告中,根据向国家结核病监测系统报告的五年平均结核病病例数,将 52 个结核病项目(50 个州、哥伦比亚特区和纽约市)分为三组。这种分组允许对具有相似结核病病例数的结核病项目进行比较,并为每个类别分配相似数量的结核病项目。使用以下公式计算每个指标的结核病项目的相对变化:[(第 5 年的百分比-第 1 年的百分比÷第 1 年的百分比)×100]。

结果

在最近有数据可用的五年期间,大多数结核病项目在降低总体结核病发病率(71.2%)和增加接受新诊断潜伏性结核病感染(LTBI)治疗的接触者比例方面取得了改善(55.8%);大多数项目(51.0%)也在降低非美国出生者的发病率方面取得了改善。在大多数司法管辖区(52 个中的 28 个,占 53.9%)中,报告药物敏感性结果的人数百分比符合或超过了 97%的五年全国平均水平(2018-2022 年)。在 2017 年至 2021 年期间,29 个(55.8%)司法管辖区中,新诊断潜伏性结核病感染(LTBI)的痰分枝杆菌(AFB)涂片阳性结核患者的接触者完成治疗的比例增加,这表明,对于大多数司法管辖区来说,已经采取了措施来加强这方面的绩效。在 12 个月内完成结核病治疗的患者比例在大约三分之二(52 个中的 32 个,占 61.5%)的司法管辖区中达到或高于全国平均水平 89.7%。

解释

本报告首次描述了结核病项目绩效的五年相对变化。这些结果表明,结核病项目在识别结核病和潜伏性结核病感染患者以及确保患者及时完成治疗方面正在取得进展。使用个别结核病项目的 NTIP 数据可以更详细地检查项目绩效趋势,并确定项目改进活动的领域。按结核病项目评估指标趋势为了解项目绩效与其他项目相比的情况提供了机会。它还可以促进项目之间在项目改进方面的成功和挑战方面的沟通。这些信息对结核病项目有效分配资源以及为公共卫生政策制定者提供结核病控制的额外背景信息非常有价值。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f2c/11166372/3ec128b710f9/ss7304a1-F.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验